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A 20-year-old woman underwent an electrophysiological study for drug-resistant persistent inap-
propriate sinus tachycardia (IST). Use of a high-dose continuous intravenous administration of landiolol,
a short-acting beta-adrenoreceptor blocker, made the patient's heart rate suddenly drop with a slight
change in the P-wave morphology. Three-dimensional right atrial (RA) activation mapping revealed that
the earliest activation site moved 8 mm to a lower anterior site around the high lateral RA. Radio-
frequency energy applied to the earliest activation site during tachycardia was successful. A temporal
sinus node modiﬁcation with landiolol administration was useful for mapping and for safe catheter
ablation of IST.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Landiolol is an intravenous short-acting beta-adrenoreceptor
blocker, and its wide use is exhibited by rapid wash out and a less-
sustained effect on cardiac function after decreasing the dose or
stopping its administration [1]. We present a patient with drug-
resistant and persistent inappropriate sinus tachycardia (IST), who
also had palpitations. The patient underwent an electro-
physiological study and ablation, and high-dose administration of
landiolol played a great role in disease treatment.2. Case report
A 20-year-old woman with persistent palpitations presented to
the hospital. The electrocardiogram (ECG) exhibited a heart rate
(HR) of 126 beats/min (bpm) with positive P waves in leads II, III,
and aVF (Fig. 1). Bisoprolol, 2.5 mg/day, was administered for six
months, but the 24-h Holter ECG still showed an average HR of
110 bpm. Ivabradine is recommended as an effective medicine, but
unfortunately, it is unavailable in Japan. An electrophysiological
study was performed because no improvement was seen after four
months of medical treatment.blished by Elsevier B.V. This is an
þ81 489 60 1708.
hara).The session was performed with the assistance of a three-
dimensional (3D) electro-anatomic mapping system (EnSite NavX
system, St. Jude Medical). A 4-mm tip ablation catheter (Therapy, St.
Jude Medical) was used for mapping and ablation. In the electro-
physiological testing, the baseline rhythm was tachycardia. The
reentrant mechanism was excluded by high-frequency stimulation
performed from the right atrium (RA), wherein tachycardia did not
stop. The RA mapping was performed, and the earliest activation
site was observed on the high lateral side, which was suspected to
be around the sinus node (Fig. 2A). The HR decreased from 126 to
116 bpm after starting a continuous intravenous administration of
landiolol from 3γ. The HR gradually decreased by increasing the
administration rate of landiolol. When landiolol was increased to 8γ,
the patient's HR suddenly dropped from 95 bpm to 78 bpm with a
slight change in the P wave on the ECG (Fig. 2B). Landiolol was kept
at 10γ, and RA mapping was performed again. The earliest activa-
tion site moved approximately 8 mm to a lower anterior site from
the map performed during tachycardia (Fig. 2A). The systolic blood
pressure was monitored carefully during the administration of high-
dose landiolol and was approximately 100 mmHg without any
symptoms from the patient.
Landiolol was stopped, and tachycardia eventually recurred
with the earliest activation site returning to a higher lateral site.
Because this patient needed a continuous high-dose intravenous
administration of landiolol to maintain a normal HR, delivery of
radiofrequency energy was considered. A local potential precededopen access article under the CC BY-NC-ND license
Fig. 1. Electrocardiogram at rest.
Fig. 2. Inﬂuence of a continuous intravenous administration of high-dose landiolol.
(A) The activation map during tachycardia and the administration of the high-dose
landiolol. The earliest activation site moved to a lower anterior site during the
administration of landiolol. (B) A sudden drop in the HR with a slight change in the
P wave on the ECG.
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tachycardia, and a QS pattern was observed in the unipolar
potential. Radiofrequency ablation was performed using a max-
imum power of 25 W, maximum electrode–tissue interface tem-
perature of 50 °C, and keeping a safe distance from the earliest
activation site during the use of landiolol. Three energy applica-
tions of 30 s were delivered. The termination of the tachycardia
was obtained by radiofrequency applications, but it eventually
recurred after a few minutes. The session was ﬁnished after
anticipating a chronical effect of the radiofrequency energy. Biso-
prolol 2.5 mg/day was continued after the session, and the HR was
maintained between 70 and 80 bpm, without any palpitations.3. Discussion
High-dose use of beta-adrenoreceptor blockers is difﬁcult due
to the risk of the appearance of hypotension and autonomic ner-
vous system disorders. Landiolol was capable of subtle adjust-
ments due to its rapid effect and shorter half-life. Because of the
short-acting property of this agent, we could reveal a spatial dif-
ference in the earliest site between the IST and normal sinus
rhythm in a reversible manner, even during a time-bound
procedure.
The underlying mechanism of IST remains poorly understood,
and this case was difﬁcult to conclude. The reentrant mechanism
was excluded, and tachycardia immediately showed a recurrence
after the cessation of landiolol. Thus, cardiac beta-adrenergic
receptor disorders, which induce abnormal automaticity, were
strongly considered, but 2.5 mg/day bisoprolol was ineffective. As
a high dose of the beta-adrenoreceptor blocker was needed to
control the HR, several causes of tachycardia such as decrease in
the parasympathetic activity may have played a role in the
maintenance of tachycardia [2]. Landiolol showed a guide for safe
RF application in this case, but various responses may be observed
in other IST cases. In addition, acceleration of the automaticity
from other sites such as the arterioventricular junction may occur
in some IST cases, and landiolol administration may not be an
effective method. Thus, further sties focusing on landiolol
administration during the IST ablation is needed.
The outcome of sinus node modiﬁcation with radiofrequency
ablation has been reported, but it involves a high invasive risk
associated with the ablation. Thus, careful conﬁrmation of the
earliest activation site and ablation of that site is important [2,3].
The clinical use of the 3D-mapping system for IST ablation has
been reported [3], and our case suggested that a temporal mod-
iﬁcation of the sinus node tachycardia by landiolol administration
combined with 3D mapping is useful to avoid complications.Financial support
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